Skip Navigation
May 17, 2022

Generation of Potent and High-Yield Exosome-Associated AAV (exoAAV) Using Engineered Exosomes

Codiak presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 on the Company’s engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene therapy. The data demonstrate that engineering exosomes to encapsulate AAV results in increased yield, resists antibody neutralization in vitro and retains transduction ability.

November 18, 2019

Codak Biosciences | Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotides-loaded exosomes results in potent single-agent antitumor activity

Codiak presented data at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy demonstrating the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.